Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

被引:23
|
作者
Facchinetti, Fabrizio [1 ]
Civelli, Maurizio [1 ]
Singh, Dave [2 ]
Papi, Alberto [3 ]
Emirova, Aida [4 ]
Govoni, Mirco [4 ]
机构
[1] Corp Preclin R&D, Parma, Italy
[2] Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England
[3] Univ Ferrara, Dept Translat Med, Resp Med, Ferrara, Italy
[4] Global Clin Dev, Parma, Italy
关键词
phosphodiesterase 4 inhibitors (PDE4i); asthma; COPD-chronic obstructive pulmonary disease; inhaled administration; inflammation; SURFACTANT PROTEIN-D; METERED-DOSE INHALER; PHOSPHODIESTERASE-4; INHIBITOR; EOSINOPHILIC INFLAMMATION; PRECLINICAL PHARMACOLOGY; TRIPLE THERAPY; CYCLIC-AMP; ROFLUMILAST; COPD; CHF6001;
D O I
10.3389/fphar.2021.740803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
    Giembycz, MA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (07) : 1361 - 1379
  • [22] Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers
    Lucci, Germano
    Mariotti, Fabrizia
    Santoro, Debora
    Acerbi, Daniela
    Poli, Gianluigi
    Nandeuil, Marie-Anna
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [23] Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
    Singh, Dave
    Lea, Simon
    Mathioudakis, Alexander G.
    DRUGS, 2021, 81 (16) : 1821 - 1830
  • [24] An inhibitor of RORγ for chronic pulmonary obstructive disease treatment
    Desai, Harshada
    Marathe, Megha
    Potdar, Varada
    Tiwari, Prabhakar
    Joshi, Ashwini
    Kadam, Sheetal R.
    Joshi, Arti Rajesh
    Kulkarni, Abhay
    Bhosale, Vikram
    Hadambar, Avinash
    Lodhiya, Bhavik
    Udupa, Venkatesha
    Behera, Dayanidhi
    Chaudhari, Sachin S.
    Das, Sanjib
    Bajpai, Malini
    Gowda, Nagaraj
    Iyer, Pravin S.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [25] Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease
    Rabe, Klaus F.
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 163 (01) : 53 - 67
  • [26] Asthma Chronic Obstructive Pulmonary Disease OverlapDefining, Naming, Diagnosing, and Treating Asthma-Chronic Obstructive Pulmonary Disease Overlap
    Sanders, William D.
    PHYSICIAN ASSISTANT CLINICS, 2023, 8 (04) : 739 - 747
  • [27] Novel Therapeutic Strategies in Asthma-Chronic Obstructive Pulmonary Disease Overlap
    Diver, Sarah
    Brightling, Chris E.
    Greening, Neil J.
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2022, 42 (03) : 671 - 690
  • [28] The Involvement of PDE4 in the Protective Effects of Melatonin on Cigarette-Smoke-Induced Chronic Obstructive Pulmonary Disease
    Lim, Je-Oh
    Kim, Woong-Il
    Lee, Se-Jin
    Pak, So-Won
    Cho, Young-Kwon
    Kim, Jong-Choon
    Kim, Joong-Sun
    Shin, In-Sik
    MOLECULES, 2021, 26 (21):
  • [29] Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma
    Deng, Yang-mei
    Xie, Qiang-min
    Tang, Hui-fang
    Sun, Jian-gang
    Deng, Jun-fang
    Chen, Ji-qiang
    Yang, Shui-you
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 547 (1-3) : 125 - 135
  • [30] The role of macrophages in obstructive airways disease: Chronic obstructive pulmonary disease and asthma
    Pappas, Konstantinos
    Papaioannou, Andriana I.
    Kostikas, Konstantinos
    Tzanakis, Nikolaos
    CYTOKINE, 2013, 64 (03) : 613 - 625